Wissam I. El-Atrouni, Zelalem Temesgen

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Darunavir is a nonpeptidic protease inhibitor recently approved for the treatment of antiretroviral therapy-experienced patients. It has potent in vitro activity against viral isolates that are resistant to currently licensed protease inhibitors. In randomized clinical trials with optimized background regimens, it has shown virologic and immunologic responses superior to comparator-based regimens.

Original languageEnglish (US)
Pages (from-to)671-679
Number of pages9
JournalDrugs of Today
Issue number10
StatePublished - Oct 2007

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Darunavir'. Together they form a unique fingerprint.

Cite this